Anticancer Drugs Durvalumab Oncology Pharmacology Physiotherapy

Durvalumab (Warnings-13)

In this article we will discuss Durvalumab (Warnings-13)

In this article, we will discuss Durvalumab (Warnings-13). So, let’s get started.

  • Immune-Mediated Hepatitis
  • Durvalumab can cause immune-mediated hepatitis. Immune-mediated hepatitis occurred in 2.8% (52/1889) of patients receiving IMFINZI, including fatal (0.2%), Grade 4 (0.3%) and Grade 3 (1.4%) adverse reactions. Events resolved in 21 of the 52 patients and resulted in permanent discontinuation of Durvalumab in 6 patients. Systemic corticosteroids were required in all patients with immune-mediated hepatitis, while 2 patients (2/52) required use of mycophenolate with high-dose steroids.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.